Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Breast 2Thoracic 1Sarcoma 1Plasma cell 1Myeloid 1Genitourinary 1

Conditions

Breast Neoplasms 2Inflammatory Breast Neoplasms 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Clostridium perfringens epsilon-toxin × Breast × Clear all
NCT07474090 2026-06-01

STEPS-BC

Wake Forest University Health Sciences

Phase NA Active not recruiting
120 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02702830 2019-04-26

MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment

Wake Forest University Health Sciences

Completed
33 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡